"While an experimental heart drug successfully lowered inflammatory markers as designed, it failed to deliver a measurable reduction in cardiovascular events like heart attack or stroke, casting doubt on a long-held scientific theory and impacting future drug development."
Novo Nordisk has announced the topline results of its pivotal ZEUS Phase 3 cardiovascular outcomes trial, revealing that its experimental drug ziltivekimab, designed to target inflammation, did not achieve its primary efficacy endpoint. The trial, which enrolled over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation, demonstrated that while ziltivekimab effectively reduced key inflammatory biomarkers, it did not translate into a statistically significant reduction in cardiovascular death, non-fatal heart attack, or non-fatal stroke compared to placebo. This outcome represents a significant development in the field of cardiovascular drug development, which has increasingly focused on the role of inflammation in cardiovascular disease pathogenesis.
The ZEUS trial was a meticulously designed, double-blind, placebo-controlled study evaluating the efficacy and safety of ziltivekimab, an antibody targeting interleukin-6 (IL-6). Participants in the trial were individuals with established ASCVD and CKD, further characterized by a high-sensitivity C-reactive protein (hsCRP) level of at least 2 milligrams per liter, indicating a state of chronic inflammation. These patients were randomized to receive either a once-monthly 15-milligram dose of ziltivekimab or a placebo. The primary composite endpoint was designed to capture major adverse cardiovascular events (MACE), encompassing cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Novo Nordisk’s announcement confirmed that ziltivekimab successfully engaged its biological target, leading to the expected reductions in free interleukin-6 and hsCRP levels. However, Martin Holst Lange, Novo Nordisk’s Executive Vice President, Chief Scientific Officer, and Head of Research and Development, stated that "although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population." The hazard ratio for the primary endpoint was reported as 0.99, with a 95 percent confidence interval of 0.88 to 1.11, indicating that the rates of cardiovascular events were virtually identical between the ziltivekimab and placebo groups. This lack of clinical benefit, despite achieving the intended biological effect, is a crucial distinction that underscores the complexity of translating mechanistic insights into tangible patient outcomes.
Regarding safety, the overall rates of adverse events and serious adverse events were comparable between the treatment and placebo arms. However, the incidence of serious infections was higher in the group receiving ziltivekimab, a finding that Novo Nordisk described as consistent with the known effects of blocking the IL-6 pathway. This observation aligns with the biological role of IL-6 in immune regulation. Importantly, no difference in all-cause mortality was observed between the two groups. These initial topline figures, released by the sponsor, provide a critical overview of the trial’s outcome. Further detailed information on adverse event rates, including discontinuations, is expected to be presented with the full study results.
The theoretical foundation for the ZEUS trial was built upon the widely discussed inflammatory hypothesis of atherosclerosis. This hypothesis posits that cardiovascular disease is not solely a consequence of lipid accumulation in arterial walls but also an active, chronic inflammatory process. Consequently, dampening this inflammation, independent of cholesterol-lowering strategies, was theorized to reduce cardiovascular events. This concept gained considerable traction over the past decade, supported by extensive preclinical research demonstrating inflammation’s integral role in all stages of atherosclerotic plaque development.
A landmark study that significantly bolstered this hypothesis was the 2017 CANAVAN trial, published in the New England Journal of Medicine. This trial showed that canakinumab, an interleukin-1 beta (IL-1β) inhibitor, reduced cardiovascular events in patients with prior myocardial infarction and elevated hsCRP levels, without affecting lipid profiles. This result was widely interpreted as proof of principle for the anti-inflammatory approach to cardiovascular risk reduction. More recently, trials involving colchicine, another anti-inflammatory agent, have yielded a more mixed record. While some studies in acute and chronic coronary syndromes have suggested event reductions, a large-scale trial in post-myocardial infarction patients did not demonstrate significant benefit.
ZEUS was designed to test the next step in this proposed inflammatory cascade. Interleukin-6 (IL-6) is a key cytokine situated downstream of IL-1β and upstream of C-reactive protein (CRP) in the inflammatory pathway. Inhibiting IL-6 was considered a potentially cleaner and more targeted intervention compared to earlier attempts, making the ZEUS trial a direct and critical test of this approach in a well-defined patient population. The dissociation observed between the drug’s impact on biomarkers and its failure to translate into clinical benefit highlights a critical gap between biological mechanism and patient outcome. This result serves as a cautionary note against treating the reduction of hsCRP, or other inflammatory markers, as a direct proxy for patient benefit, particularly in the context of cardiovascular risk. It also arrives at a time when inflammatory markers are increasingly being incorporated into cardiovascular prevention guidelines as risk-enhancing factors.
It is imperative to clarify the implications of the ZEUS trial for patients currently undergoing anti-inflammatory therapy for cardiovascular risk reduction. For instance, some patients are prescribed low-dose colchicine for cardiovascular risk mitigation. The results of the ZEUS trial do not directly apply to these individuals. Colchicine exerts its effects through a distinct mechanism of action and has been evaluated in different patient populations. Therefore, no patient should discontinue any prescribed medication based on the outcome of a trial involving a different drug and a distinct patient cohort. Such decisions must be made in consultation with a qualified cardiologist who possesses a comprehensive understanding of the patient’s individual medical history and risk profile.
For patients who have undergone hsCRP testing, the practical takeaway from the ZEUS trial is more nuanced than it might initially appear. An elevated inflammatory marker, such as hsCRP, continues to be a valuable indicator of heightened cardiovascular risk. What the ZEUS trial effectively challenges is the assumption that targeting a specific inflammatory marker with a particular mechanism, such as IL-6 inhibition in this case, will necessarily translate into a reduction of the risk that the marker signifies. This distinction is crucial: a risk marker and a treatment target are not interchangeable.
The established pillars of cardiovascular prevention remain unequivocally validated by robust outcome data. These include lipid-lowering therapies, blood pressure control, smoking cessation, effective diabetes management, and the promotion of physical activity. The negative outcome of an experimental pathway does not diminish the proven efficacy of these fundamental strategies.
The specificity of the ZEUS trial’s patient population—individuals with established ASCVD, CKD, and elevated inflammation—means that the generalizability of its findings is limited. It remains an open question whether IL-6 inhibition might prove beneficial in different patient populations or if initiated earlier in the disease process. Two other ziltivekimab outcomes trials are currently ongoing. The HERMES trial is investigating the drug’s efficacy in patients with heart failure, and the ARTEMIS trial is evaluating its use in patients following an acute myocardial infarction. Both of these trials are anticipated to report their findings in the first half of 2027. These future readouts will be instrumental in defining the precise boundaries of the ZEUS trial’s implications.
The complete results of the ZEUS trial are slated for presentation at a major scientific meeting later this year. This comprehensive presentation will offer detailed insights into adverse event profiles, patient discontinuations, and subgroup analyses that are not captured in the topline figures. Industry coverage of Novo Nordisk’s announcement indicated that while the trial outcome will not affect the company’s 2026 adjusted operating profit outlook, it will result in a non-cash impairment charge in the third quarter.
Patients with concerns regarding their inflammatory markers or overall cardiovascular risk should proactively discuss these issues with their healthcare providers during their next scheduled appointment. The most prudent interpretation of the ZEUS trial results is that a promising therapeutic pathway, while biologically active, did not yield the anticipated clinical benefits in a carefully defined patient group. Consequently, the fundamental strategies for cardiovascular prevention remain unchanged.
Key Questions Answered:
What happened? Novo Nordisk announced that ziltivekimab, an experimental IL-6 inhibitor, successfully reduced inflammatory markers as expected but did not lead to a statistically significant reduction in cardiovascular death, heart attack, or stroke in a trial involving over 6,300 patients.
Who was included in the trial? The trial enrolled individuals diagnosed with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), who also exhibited inflammation as indicated by a high-sensitivity C-reactive protein (hsCRP) level of at least 2 milligrams per liter.
Does this mean inflammation is not a factor in heart disease? No. Inflammation continues to be recognized as a significant marker of increased cardiovascular risk. Furthermore, a prior trial involving a different anti-inflammatory drug demonstrated cardiovascular benefits. However, the ZEUS trial did not establish that blocking IL-6 in this specific population effectively translates biomarker changes into a reduction in cardiovascular events.
Should anyone discontinue their current heart medication? No. Ziltivekimab was an experimental drug and was not approved or made available outside of clinical trials. The results of this trial do not necessitate any changes to currently approved therapies. Patients should never stop taking a prescribed medication without first consulting with their physician.
What is the significance for colchicine users? Colchicine operates through a different mechanism of action and was evaluated in distinct patient groups. Therefore, the findings from the ZEUS trial are not directly applicable to individuals taking colchicine.
Were there any safety concerns? While overall adverse event rates were similar between the ziltivekimab and placebo groups, there was an increased incidence of serious infections observed in the drug-treated group. Novo Nordisk stated that this finding is consistent with the known effects of inhibiting the IL-6 pathway.
What are the next steps? Comprehensive results from the ZEUS trial are expected to be presented at a scientific meeting later this year. Additionally, two other ziltivekimab outcomes trials, HERMES (in heart failure) and ARTEMIS (post-heart attack), are anticipated to yield their results in the first half of 2027, which will further elucidate the implications of this research.
